These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7039044)

  • 41. The use of immunopotentiators in malaria.
    Strickland GT; Hunter KW
    Int J Nucl Med Biol; 1980; 7(2):133-40. PubMed ID: 6772589
    [No Abstract]   [Full Text] [Related]  

  • 42. Recent developments in immunomodulatory therapy.
    Bardana EJ
    J Allergy Clin Immunol; 1985 Apr; 75(4):423-40. PubMed ID: 2579994
    [No Abstract]   [Full Text] [Related]  

  • 43. Inefficacy of sc Corynebacterium parvum in stage I malignant melanoma: preliminary results of a single-institution pilot study.
    Murray JL; Ishmael DR; Bottomley RH; Grozea PN; Lee ET
    Cancer Treat Rep; 1983 Feb; 67(2):191-2. PubMed ID: 6825130
    [No Abstract]   [Full Text] [Related]  

  • 44. Enhanced Fc receptor expression by a sub-population of murine intra-tumour macrophages following intravenous Corynebacterium parvum therapy.
    Moore K; McBride WH
    Br J Cancer; 1983 Jun; 47(6):797-802. PubMed ID: 6860547
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined immunosuppression for canine renal allograft prolongation: antilymphocyte serum plus prednisolone or azathioprine.
    Weil R; Simmons RL
    Ann Surg; 1968 Feb; 167(2):239-45. PubMed ID: 4866845
    [No Abstract]   [Full Text] [Related]  

  • 46. Adjuvant protection against bacterial infection in granulocytopenic mice.
    Buhles WC; Shifrine M
    J Infect Dis; 1977 Jul; 136(1):90-5. PubMed ID: 328788
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of clinical immunosuppression on proinflammatory cytokines and acute-phase proteins.
    Semenkov VF; Artemjeva OV; Shishina RN; Golubeva VL; Serova LD
    Transplant Proc; 1998 Dec; 30(8):4195. PubMed ID: 9865345
    [No Abstract]   [Full Text] [Related]  

  • 48. Chemotherapy and corynebacterium parvum for induction and maintenance of remission in acute myelogenous leukaemia--a controlled study.
    Shetty PA; Pai VR; Jani PH; Antia PK; Shahane AD
    Indian J Cancer; 1983; 20(2):119-23. PubMed ID: 6580265
    [No Abstract]   [Full Text] [Related]  

  • 49. Chemoimmunotherapy (DTIC and Corynebacterium parvum) for disseminated malignant melanoma.
    Karakousis CP; Didolkar MS; Han T
    Cancer Treat Rep; 1981; 65(9-10):925-6. PubMed ID: 7273032
    [No Abstract]   [Full Text] [Related]  

  • 50. The role of macrophages in the adjuvant effect on antibody production of Corynebacterium parvum.
    Watson SR; Sljivić VS
    Clin Exp Immunol; 1976 Jan; 23(1):149-53. PubMed ID: 770033
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumour growth, phagocytic activity and antibody response in Corynebacterium parvum-treated mice.
    Woodruff MF; McBride WH; Dunbar N
    Clin Exp Immunol; 1974 Jul; 17(3):509-18. PubMed ID: 4549691
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preliminary results of short-term combination immunosuppressions of mizoribine, azathioprine, and prednisolone with pretreatment to canine kidney transplantation.
    Minami T; Watanabe T; Muto M; Wakao Y; Suzuki T; Takahashi M
    J Vet Med Sci; 1993 Jun; 55(3):409-14. PubMed ID: 8357913
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Studies on immunosuppression with low-dose cyclosporine combined with mizoribine in experimental and clinical cadaveric renal allotransplantation.
    Osakabe T; Uchida H; Masaki Y; Yokota K; Sato K; Nakayama Y; Ohkubo M; Kumano K; Endo T; Watanabe K
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1598-600. PubMed ID: 2652520
    [No Abstract]   [Full Text] [Related]  

  • 54. Implications of lymphocyte sensitivity to glucocorticoids in renal transplant recipients.
    Kozaki M; Hirano T; Oka K; Sakurai E; Tamaki T; Tanaka M; Kono K; Matsuno N; Uchiyama M; Kozaki K
    Transplant Proc; 1993 Feb; 25(1 Pt 2):921-3. PubMed ID: 8442268
    [No Abstract]   [Full Text] [Related]  

  • 55. Is trauma associated with acute rejection of a renal transplant?
    Mohammed EP; Venkat-Raman G; Marley N
    Nephrol Dial Transplant; 2002 Feb; 17(2):283-4. PubMed ID: 11812881
    [No Abstract]   [Full Text] [Related]  

  • 56. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly sequential study of melanoma patients. I. Changes in non-specific (NK, K and T cell) lymphocytotoxicity, peripheral blood counts and delayed hypersensitivity reactions.
    Thatcher N; Swindell R; Crowther D
    Clin Exp Immunol; 1979 May; 36(2):227-36. PubMed ID: 314367
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Monitoring natural killer cell activity in the blood of patients with malignant pleural effusion after intrapleural administration of Corynebacterium parvum].
    Marel M; Pospísil M; Fiserová A; Melínová L; Skácel Z; Bednár M
    Cas Lek Cesk; 1990 Apr; 129(16):498-500. PubMed ID: 2340567
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medroxyprogesterone antilymphocyte globulin, prednisone, and azathioprine in the treatment of dog renal allografts.
    MacDonald AS; Alexander JL; Busch GJ; Murray JE
    Surg Forum; 1969; 20():306-7. PubMed ID: 4192215
    [No Abstract]   [Full Text] [Related]  

  • 59. Adjuvant intralesional and systemic Corynebacterium parvum immunotherapy for surgically treated head and neck cancer.
    Beatty JD; Terz JJ; Brown PW; Lawrence W; Schuller GB; Kaplan AM
    Surg Forum; 1978; 29():155-7. PubMed ID: 401122
    [No Abstract]   [Full Text] [Related]  

  • 60. Treatment of malignant pleural effusions with intrapleural Corynebacterium parvum or tetracycline.
    Leahy BC; Honeybourne D; Brear SG; Carroll KB; Thatcher N; Stretton TB
    Eur J Respir Dis; 1985 Jan; 66(1):50-4. PubMed ID: 3979476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.